ARTICANZ - Beta (ver 0.91)
Annotated Registry of Trials in Cancer, Australia and New Zealand Ed.
- Results - target/CD19
Home
By cancer type
By drug class
By site
Data
FAQ
About
⚠
ARTICANZ provides informational content about cancer drug trials in Australia/NZ that is updated weekly but may not be completely accurate, and should not replace medical advice from qualified healthcare professionals. The platform is intended to be useful, providing information "as is" without warranties. Non-medical users must always consult healthcare providers for all clinical decisions.
Search results
target/CD19
24
trial(s) found.
NCT07519772
Haem
Phase 1 / Phase 2
Recruiting
A Phase 1b/2 Study to Evaluate the Safety and Efficacy of MK-1045 Monotherapy or in Combination With Other Anticancer Agents in Participants With Non-Hodgkin Lymphoma (
WaveSpan-008
)
bispecific T-cell engager,CD19-targeting
Lymphoma
VIC
3128 - Box Hill - Box Hill Hospital - Eastern Health
QLD
4812 - Townsville - Townsville University Hospital
NCT07518329
Haem
Phase 1
Not yet recruiting
A Phase 1 Open-Label Dose-Escalation and Expansion Study to Assess the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Preliminary Efficacy of ALA-101, Allogeneic, Off-the-shelf, CD19-directed CAR-iNKT Cells in Patients With CD19+ Non-Hodgkin Lymphoma and Leukemia (
SAPPHIRE
)
allogeneic CAR-iNKT-cell therapy,CD19-targeting
Leukaemia
Non-Hodgkin's lymphoma
NSW
2010 - Darlinghurst - St Vincent's Hospital Sydney - The Kinghorn Cancer Centre
VIC
3004 - Melbourne, Southbank - Alfred Health
3121 - Richmond - Epworth Freemasons Hospital
QLD
4101 - South Brisbane - Mater Hospital Brisbane / ICON Cancer Centre
SA
5000 - Adelaide - Royal Adelaide Hospital - Adelaide Cancer Centre
NCT07509151
Haem
Phase 3
Recruiting
A Phase III, Randomised, Open-label, Multicentre, Study of Surovatamig as Consolidation Therapy Versus Observation After First-line Induction Therapy in Participants With Chronic Lymphocytic Leukaemia or Small Lymphocytic Lymphoma With Unmutated IGHV (
SOUNDTRACK-C1
)
bispecific T-cell engager,CD19-targeting
Chronic lymphocytic leukaemia
Small lymphocytic lymphoma
VIC
3065 - Fitzroy - St Vincent's Hospital Melbourne
3084 - Heidelberg - Austin Hospital Olivia Newton-John Cancer Centre
SA
5000 - Adelaide - Royal Adelaide Hospital - Adelaide Cancer Centre
WA
6000 - Perth - Royal Perth Hospital
6009 - Nedlands - Sir Charles Gairdner Hospital - WA Cancer Centre
6168 - Cooloongup - Rockingham Hospital
NCT07479797
Haem
Phase 3
Recruiting
A Phase 3, Randomized, Open-Label, Multicenter Study Evaluating the Efficacy of KITE-753 Versus Axicabtagene Ciloleucel in Participants With Relapsed or Refractory Large B-Cell Lymphoma After First-Line Therapy (
KT-US-740-0603
)
autologous CAR-T-cell therapy,CD19-targeting
autologous CAR-T-cell therapy,CD19/CD20-targeting
Diffuse large B-cell lymphoma
VIC
3002 - East Melbourne - Epworth Freemasons
NCT07215585
Haem
Phase 3
Recruiting
A Phase III, Multicentre, Open-Label, Randomised Study Evaluating the Efficacy and Safety of R-mini-CHOP x2 Followed by AZD0486 Versus R-mini-CHOP x6 in Elderly or Unfit Participants With Newly Diagnosed Large B-cell Lymphoma (
SOUNDTRACK-D2
)
bispecific T-cell engager,CD19-targeting
Diffuse large B-cell lymphoma
NSW
2109 - North Ryde - Macquarie University Hospital
2298 - Waratah - Calvary Mater Newcastle Medical Oncology
VIC
3000 - Melbourne - Peter MacCallum Cancer Centre
3168 - Clayton - Monash Medical Centre
WA
6009 - Nedlands - Sir Charles Gairdner Hospital - WA Cancer Centre
NCT06564038
Haem
Phase 1 / Phase 2
Recruiting
A Phase I/II Open-Label Multi-Centre Master Protocol to Evaluate the Safety and Efficacy of AZD0486 Monotherapy or in Combination With Other Anticancer Agents in Participants With Mature B-Cell Malignancies (
Soundtrack-E
)
bispecific T-cell engager,CD19-targeting
Chronic lymphocytic leukaemia
Diffuse large B-cell lymphoma
Mantle cell lymphoma
Non-Hodgkin's lymphoma
Small Lymphocytic Lymphoma
VIC
3004 - Melbourne, Southbank - Alfred Health
3084 - Heidelberg - Austin Hospital Olivia Newton-John Cancer Centre
WA
6009 - Nedlands - Sir Charles Gairdner Hospital - WA Cancer Centre
NCT06528301
Haem
Phase 1
Recruiting
A Phase 1, Multicenter, Open-label Study of UB-VV111 in Combination With Rapamycin in Relapsed/Refractory (R/R) CD19+ B-cell Malignancies (
UB-VV111-01
)
gene therapy,CAR-T-cell generating,CD19-targeting
mTORC1/mTORC2 inhibitor
Chronic lymphocytic leukaemia
Diffuse large B-cell lymphoma
Lymphoma
NSW
2065 - St Leonards - Northern Sydney Cancer Centre, Royal North Shore Hospital
VIC
3065 - Fitzroy - St Vincent's Hospital Melbourne
NCT06526793
Haem
Phase 2
Recruiting
A Modular Phase 2, Single-arm, Multicenter, Open-label Study to Evaluate the Efficacy and Safety of Surovatamig (AZD0486) in Participants With Relapsed or Refractory (R/R) B-cell Non-Hodgkin Lymphoma (
SOUNDTRACK-B
)
bispecific T-cell engager,CD19-targeting
Diffuse large B-cell lymphoma
Follicular lymphoma
Non-Hodgkin's lymphoma
NSW
2109 - North Ryde - Macquarie University Hospital
2217 - Kogarah - St George Hospital
VIC
3084 - Heidelberg - Austin Hospital Olivia Newton-John Cancer Centre
WA
6009 - Nedlands - Sir Charles Gairdner Hospital - WA Cancer Centre
NCT06500273
Haem
Phase 2
Recruiting
A Randomized, Open-label Study Evaluating the Efficacy and Safety of Cemacabtagene Ansegedleucel in Participants With Minimal Residual Disease After Response to First Line Therapy for Large B-cell Lymphoma (
ALPHA3
)
allogeneic CAR-T-cell therapy,CD19-targeting
Diffuse large B-cell lymphoma
VIC
3065 - Fitzroy - St Vincent's Hospital Melbourne
3084 - Heidelberg - Austin Hospital Olivia Newton-John Cancer Centre
3168 - Clayton - Monash Medical Centre
QLD
4066 - Auchenflower - Icon Cancer Centre at Wesley Hospital
WA
6009 - Nedlands - Hollywood Private Hospital
TAS
7000 - Hobart - Royal Hobart Hospital
NCT06486051
Haem
Phase 2
Recruiting
A Phase 2 Trial to Evaluate the Efficacy and Safety of WZTL-002 in Patients With Relapsed or Refractory Large B-cell Lymphoma (
ENABLE-2
)
autologous CAR-T-cell therapy,CD19-targeting
Diffuse large B-cell lymphoma
Non-Hodgkin's lymphoma
NZ
NZ.1023 - Grafton - Auckland City Hospital - Cancer & Blood Research
NZ.6021 - Wellington - Capital & Coast District Health Board - Wellington Hospital
NZ.8011 - Christchurch - Canterbury District Health Board - Christchurch Hospital Cancer Centre
NCT06137118
Paed
Phase 1 / Phase 2
Recruiting
A Phase 1/2 Study to Evaluate the Safety and Efficacy of AZD0486 in Adolescent and Adult Participants With Relapsed or Refractory B-Cell Acute Lymphoblastic Leukaemia (
SYRUS
)
bispecific T-cell engager,CD19-targeting
B-cell acute lymphoblastic leukaemia/lymphoma
VIC
3000 - Melbourne - Peter MacCallum Cancer Centre
NCT06124157
Paed
Phase 2
Recruiting
An International Phase 2 Study of Chemotherapy and Tyrosine Kinase Inhibitors With Blinatumomab in Patients With Newly-Diagnosed Philadelphia Chromosome-Positive or ABL-Class Philadelphia Chromosome-Like B-Cell Acute Lymphoblastic Leukemia (
NCI-2023-09214
)
bispecific T-cell engager,CD19-targeting
Acute lymphoblastic leukaemia
NSW
2305 - New Lambton Heights - John Hunter Children's Hospital
QLD
4101 - South Brisbane - Queensland Children's Hospital
WA
6009 - Perth - Perth Children's Hospital
NCT05991388
Paed
Phase 2 / Phase 3
Recruiting
A Global Study of Novel Agents in Paediatric and Adolescent Relapsed and Refractory B-cell Non-Hodgkin Lymphoma (
Glo-BNHL
)
Carboplatin
Dexamethasone
Etoposide
Ifosfamide
Loncastuximab Tesirine
Odronextamab
Rituximab
alkylating agent
anti-CD19 antibody-drug conjugate
anti-CD20 monoclonal antibody
bispecific T-cell engager,CD20-targeting
cancer therapy
cancer therapy,CD19-targeting
cancer therapy,CD20-targeting
cytotoxic chemotherapy
glucocorticoid
immuno-oncology therapy,CD19-targeting
immuno-oncology therapy,CD20-targeting
platinum-based antineoplastic agent
therapeutic modality,bispecific T-cell engager
therapeutic modality,bispecific antibody
topoisomerase inhibitor
+ anti-CD19 antibody-drug conjugate
Non-Hodgkin's lymphoma
NSW
2145 - Westmead - The Children's Hospital at Westmead
QLD
4101 - South Brisbane - Queensland Children's Hospital
WA
6009 - Perth - Perth Children's Hospital
NZ
NZ.1023 - Grafton - Starship Children's Hospital
NCT05826535
Haem
Phase 1 / Phase 2
Recruiting
A Phase 1/2 Multi-Center Study Evaluating the Safety and Efficacy of Rondecabtagene Autoleucel, a CD19/CD20 Dual-Targeting Chimeric Antigen Receptor T-Cell Therapy in Participants With Aggressive B-Cell Non-Hodgkin Lymphoma (
LYL314-101
)
autologous CAR-T-cell therapy,CD19/CD20-targeting
Diffuse large B-cell lymphoma
Non-Hodgkin's lymphoma
VIC
3004 - Melbourne, Southbank - Alfred Health
WA
6000 - Perth - Royal Perth Hospital
6009 - Nedlands - Sir Charles Gairdner Hospital - WA Cancer Centre
NCT05643742
Haem
Phase 1 / Phase 2
Recruiting
A Phase 1/2, Open-Label, Multicenter, Dose Escalation and Cohort Expansion Study of the Safety and Efficacy of Anti-CD19 Allogeneic CRISPR-Cas9-Engineered T Cells (CTX112) in Subjects With Relapsed or Refractory B Cell Malignancies (
CRSP-ONC-006
)
allogeneic CAR-T-cell therapy,CD19-targeting
B-cell lymphoma
B-cell malignancy
Chronic lymphocytic leukaemia
Diffuse large B-cell lymphoma
Follicular lymphoma
Mantle cell lymphoma
Marginal zone lymphoma
Non-Hodgkin's lymphoma
Small Lymphocytic Lymphoma
NSW
2050 - Camperdown - Royal Prince Alfred Hospital - A.W. Morrow Gastroenterology and Liver Centre
VIC
3004 - Melbourne, Southbank - Alfred Health
WA
6009 - Nedlands - Sir Charles Gairdner Hospital - WA Cancer Centre
NCT05365659
Haem
Phase 1
Recruiting
A Phase 1 Cohort Dose Escalation and Expansion Trial to Determine the Safety, Tolerance, Maximum Tolerated Dose, and Preliminary Antineoplastic Activity of IKS03 in Patients With Advanced B Cell Non-Hodgkin Lymphomas (NHL) (
IKS03-01
)
anti-CD19 antibody-drug conjugate
B-cell lymphoma
Diffuse large B-cell lymphoma
Follicular lymphoma
Mantle cell lymphoma
Non-Hodgkin's lymphoma
NSW
2145 - Westmead - The Crown Princess Mary Cancer Centre - Westmead Hospital
SA
5000 - Adelaide - Royal Adelaide Hospital - Adelaide Cancer Centre
WA
6009 - Nedlands - Linear Clinical Research
TAS
7000 - Hobart - Royal Hobart Hospital
NCT05327894
Paed
Phase 3
Recruiting
Interfant-21
International Collaborative Treatment Protocol for Infants Under One Year With KMT2A-rearranged Acute Lymphoblastic Leukemia or Mixed Phenotype Acute Leukemia.
Blinatumomab
Prednisone
bispecific T-cell engager,CD19-targeting
cancer therapy
cancer therapy,CD19-targeting
glucocorticoid
immuno-oncology therapy,CD19-targeting
therapeutic modality,bispecific T-cell engager
therapeutic modality,bispecific antibody
+ bispecific T-cell engager,CD19-targeting
Acute lymphoblastic leukaemia
Mixed phenotype acute leukaemia
NSW
2031 - Randwick - Sydney Children's Hospital
2145 - Westmead - The Children's Hospital at Westmead
2305 - New Lambton Heights - John Hunter Children's Hospital
VIC
3052 - Parkville - Royal Children's Hospital Melbourne
3168 - Clayton - Monash Children's Hospital
QLD
4101 - South Brisbane - Queensland Children's Hospital
SA
5006 - North Adelaide - Women's and Children's Hospital-Adelaide Cancer Centre
WA
6009 - Perth - Perth Children's Hospital
NZ
NZ.1023 - Grafton - Starship Children's Hospital
NZ.8011 - Christchurch - Christchurch Children's Hospital
NCT04989803
Haem
Phase 1 / Phase 2
Recruiting
A Phase 1/2 Open-label, Multicenter Study Evaluating the Safety and Efficacy of KITE-363 or KITE-753, Autologous Anti-CD19/CD20 CAR T-cell Therapies, in Subjects With Relapsed and/or Refractory B-cell Lymphoma (
PALISADES-1
)
autologous CAR-T-cell therapy,CD19/CD20-targeting
B-cell lymphoma
NSW
2065 - St Leonards - Northern Sydney Cancer Centre, Royal North Shore Hospital
2139 - Concord - Concord Repatriation General Hospital
VIC
3002 - East Melbourne - Epworth Freemasons
SA
5000 - Adelaide - Royal Adelaide Hospital - Adelaide Cancer Centre
NCT04546399
Haem
Phase 2
Recruiting
A Phase 2 Study of Blinatumomab (NSC# 765986) in Combination With Nivolumab (NSC# 748726), a Checkpoint Inhibitor of PD-1, in B-ALL Patients Aged >/= 1 to < 31 Years Old With First Relapse (
NCI-2020-06813
)
anti-PD-1 monoclonal antibody
bispecific T-cell engager,CD19-targeting
Acute lymphoblastic leukaemia
NSW
2031 - Randwick - Sydney Children's Hospital
2145 - Westmead - The Children's Hospital at Westmead
2305 - New Lambton Heights - John Hunter Children's Hospital
QLD
4101 - South Brisbane - Queensland Children's Hospital
WA
6009 - Perth - Perth Children's Hospital
NCT03959085
Haem
Phase 3
Recruiting
A Phase 3 Randomized Trial of Inotuzumab Ozogamicin (IND#:133494, NSC#: 772518) for Newly Diagnosed High-Risk B-ALL; Risk-Adapted Post-Induction Therapy for High-Risk B-ALL, Mixed Phenotype Acute Leukemia, and Disseminated B-LLy (
AALL1732
)
anti-CD22 antibody-drug conjugate
+ bispecific T-cell engager,CD19-targeting
Acute lymphoblastic leukaemia
B-cell acute lymphoblastic leukaemia/lymphoma
Leukaemia
Mixed phenotype acute leukaemia
NSW
2145 - Westmead - The Children's Hospital at Westmead
2305 - New Lambton Heights - John Hunter Children's Hospital
VIC
3052 - Parkville - Royal Children's Hospital Melbourne
3168 - Clayton - Monash Medical Centre
QLD
4101 - South Brisbane - Queensland Children's Hospital
SA
5006 - North Adelaide - Calvary North Adelaide Hospital, Adelaide Oncology & Haematology
WA
6009 - Perth - Perth Children's Hospital
TAS
7000 - Hobart - Royal Hobart Hospital
NZ
NZ.1023 - Grafton - Starship Children's Hospital
NZ.8011 - Christchurch - Canterbury District Health Board - Christchurch Hospital Cancer Centre
NCT03666000
Haem
Phase 1
Recruiting
A Phase 1/1b, Open-label, Dose-escalation, Dose-expansion, Parallel Assignment Study to Evaluate Safety and Clinical Activity of PBCAR0191 (Azercabtagene Zapreleucel or "Azer-cel") in Subjects With Relapsed/Refractory (r/r) Non-Hodgkin Lymphoma (NHL) and r/r B-cell Acute Lymphoblastic Leukemia (B-ALL) (
PBCAR0191-01
)
allogeneic CAR-T-cell therapy,CD19-targeting
B-cell acute lymphoblastic leukaemia/lymphoma
Chronic lymphocytic leukaemia
Non-Hodgkin's lymphoma
Small Lymphocytic Lymphoma
NSW
2050 - Camperdown - Chris O'Brien Lifehouse
2170 - Liverpool - Liverpool Hospital
VIC
3065 - Fitzroy - St Vincent's Hospital Melbourne
3220 - Geelong - Andrew Love Cancer Centre, University Hospital Geelong
SA
5000 - Adelaide - Royal Adelaide Hospital - Adelaide Cancer Centre
NCT03601442
Paed
Available
Managed Access Programs for CTL019, Tisagenlecleucel (
CCTL019B2003I
)
autologous CAR-T-cell therapy,CD19-targeting
Leukaemia
Lymphoma
ACTRN12625001195448
Haem
Phase 1
Recruiting
A Phase I, Open-Label, Single Arm Trial to Assess the Efficacy and Safety of PMCC-COE19 in Patients with CD19-Expressing B-Cell Malignancies (
PLATYPS
)
autologous CAR-T-cell therapy,CD19-targeting
B-cell lymphoma
Cancer
Leukaemia
VIC
3000 - Melbourne - Peter MacCallum Cancer Centre
ACTRN12619000079145
Haem
Phase 1
Not yet recruiting
A Phase I Study of Autologous CD19 Specific Chimeric Antigen Receptor T-cells for Therapy of Relapsed and Refractory B-cell Leukaemia and Lymphoma (
The-AutoCAR19-Trial
)
autologous CAR-T-cell therapy,CD19-targeting
Acute lymphoblastic leukaemia
Chronic lymphocytic leukaemia
Non-Hodgkin's lymphoma
NSW
2031 - Randwick - Prince of Wales Hospital
2145 - Westmead - The Crown Princess Mary Cancer Centre - Westmead Hospital
VIC
3000 - Melbourne - Peter MacCallum Cancer Centre
3053 - Parkville - The Royal Women's Hospital and Institute of Maternal and Child Health
QLD
4006 - Herston - The Royal Brisbane and Women's Hospital Cancer Centre
4101 - South Brisbane - Mater Hospital Brisbane / ICON Cancer Centre
SA
5000 - Adelaide - Royal Adelaide Hospital - Adelaide Cancer Centre
5006 - North Adelaide - Calvary North Adelaide Hospital, Adelaide Oncology & Haematology
WA
6000 - Perth - Royal Perth Hospital
Additional search terms:
API and Webpage URLs:
Copy /Bookmark
Filters
Recruitment Status
Recruiting (21)
Not yet recruiting (2)
Recruitment Country and State
VIC (18)
NSW (14)
WA (14)
QLD (9)
SA (8)
NZ (4)
TAS (3)
Phase
Phase 1 (6)
Phase 1 / Phase 2 (6)
Phase 2 (5)
Phase 2 / Phase 3 (1)
Phase 3 (5)
Trial Type
Haem (19)
Paed (5)
Cancer Therapy Class
CD19
96%
CD20
21%
BTK
4%
CAR-T-cell generating,CD19
4%
mTOR
4%
mTORC1
4%
mTORC2
4%
BCR-ABL1
4%
KIT
4%
PDGFRA
4%
SRC
4%
YES1
4%
PD-1
4%
PD-1/PD-L1
4%
CD22
4%
Facility
5000 - Adelaide - Royal Adelaide Hospital - Adelaide Cancer Centre (6)
6009 - Nedlands - Sir Charles Gairdner Hospital - WA Cancer Centre (6)
4101 - South Brisbane - Queensland Children's Hospital (5)
6009 - Perth - Perth Children's Hospital (5)
3004 - Melbourne, Southbank - Alfred Health (4)
3065 - Fitzroy - St Vincent's Hospital Melbourne (4)
3084 - Heidelberg - Austin Hospital Olivia Newton-John Cancer Centre (4)
3000 - Melbourne - Peter MacCallum Cancer Centre (4)
2305 - New Lambton Heights - John Hunter Children's Hospital (4)
2145 - Westmead - The Children's Hospital at Westmead (4)
6000 - Perth - Royal Perth Hospital (3)
3168 - Clayton - Monash Medical Centre (3)
7000 - Hobart - Royal Hobart Hospital (3)
NZ.1023 - Grafton - Starship Children's Hospital (3)
4101 - South Brisbane - Mater Hospital Brisbane / ICON Cancer Centre (2)
3002 - East Melbourne - Epworth Freemasons (2)
2109 - North Ryde - Macquarie University Hospital (2)
2065 - St Leonards - Northern Sydney Cancer Centre, Royal North Shore Hospital (2)
NZ.8011 - Christchurch - Canterbury District Health Board - Christchurch Hospital Cancer Centre (2)
2145 - Westmead - The Crown Princess Mary Cancer Centre - Westmead Hospital (2)
2031 - Randwick - Sydney Children's Hospital (2)
3052 - Parkville - Royal Children's Hospital Melbourne (2)
5006 - North Adelaide - Calvary North Adelaide Hospital, Adelaide Oncology & Haematology (2)
3128 - Box Hill - Box Hill Hospital - Eastern Health (1)
4812 - Townsville - Townsville University Hospital (1)
2010 - Darlinghurst - St Vincent's Hospital Sydney - The Kinghorn Cancer Centre (1)
3121 - Richmond - Epworth Freemasons Hospital (1)
6168 - Cooloongup - Rockingham Hospital (1)
2298 - Waratah - Calvary Mater Newcastle Medical Oncology (1)
2217 - Kogarah - St George Hospital (1)
4066 - Auchenflower - Icon Cancer Centre at Wesley Hospital (1)
6009 - Nedlands - Hollywood Private Hospital (1)
NZ.1023 - Grafton - Auckland City Hospital - Cancer & Blood Research (1)
NZ.6021 - Wellington - Capital & Coast District Health Board - Wellington Hospital (1)
2050 - Camperdown - Royal Prince Alfred Hospital - A.W. Morrow Gastroenterology and Liver Centre (1)
6009 - Nedlands - Linear Clinical Research (1)
3168 - Clayton - Monash Children's Hospital (1)
5006 - North Adelaide - Women's and Children's Hospital-Adelaide Cancer Centre (1)
NZ.8011 - Christchurch - Christchurch Children's Hospital (1)
2139 - Concord - Concord Repatriation General Hospital (1)
2050 - Camperdown - Chris O'Brien Lifehouse (1)
2170 - Liverpool - Liverpool Hospital (1)
3220 - Geelong - Andrew Love Cancer Centre, University Hospital Geelong (1)
2031 - Randwick - Prince of Wales Hospital (1)
3053 - Parkville - The Royal Women's Hospital and Institute of Maternal and Child Health (1)
4006 - Herston - The Royal Brisbane and Women's Hospital Cancer Centre (1)
Cancer Type
Cancer
Haematological malignancy
Lymphoma
Non-Hodgkin's lymphoma
B-cell malignancy
Mature B-cell malignancy
Leukaemia
B-cell lymphoma
Lymphoid leukaemia
Diffuse large B-cell lymphoma
High-grade B-cell lymphoma
Acute lymphoblastic leukaemia
Chronic lymphocytic leukaemia
Small lymphocytic lymphoma
Mantle cell lymphoma
Follicular lymphoma
B-cell acute lymphoblastic leukaemia/lymphoma
Mixed phenotype acute leukaemia
Marginal zone lymphoma
URLs for this search
API URL:
Copy
Bookmarkable URL:
Copy